Overview

A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis

Status:
Completed

Trial end date:
2020-03-26

Target enrollment:

Participant gender:

Summary

This is a multi-center phase 2b study in subjects with moderate to severe chronic plaque-type psoriasis. Approximately 300 subjects will be enrolled at approximately 60 investigator sites in North America and Europe.

Phase:

Phase 2

Details

Lead Sponsor:

Bond Avillion 2 Development LP

Collaborator:

Avillion LLP